The National Medicines Safety Agency and the Viatris laboratory announced on Monday the recall of an anti-cancer treatment. The medicine in question is Pomalidomide.
This content is blocked because you have not accepted cookies and other trackers.
By clicking on “I accept”cookies and other trackers will be placed and you will be able to view the contents (more information).
By clicking on “I accept all cookies”you authorize the storage of cookies and other trackers for the storage of your data on our sites and applications for personalization and advertising targeting purposes.
You can withdraw your consent at any time by consulting our data protection policy.
Manage my choices
I accept
I accept all cookies
Powder outside the capsule
This recall follows a quality defect: during an inspection, powder containing the active ingredient was in fact discovered outside the capsules, in the blister packs of the platelets. This defect was noted on a batch which was not distributed. However, it cannot be ruled out that other boxes are affected. All lots of Pomalidomide Viatris 1 mg, 2 mg, 3 mg and 4 mg are therefore recalled as a precaution.
The ASNM recalls the dangers of pomalidomide, a teratogenic product, that is to say which can cause serious malformations in fetuses. Pregnant women or women of childbearing age should therefore not have contact with this product.
What should you do?
If you have a box of Pomalidomide Viatris (all strengths) at home, do not stop or change your treatment without medical advice, but return the box to the pharmacy that provided it to you. The pharmacist will carry out checks and issue you with a new box. If you notice the presence of powder outside the capsule in a pack of your medicine, do not open it. If you are pregnant and have been in contact with pomalidomide powder, tell your doctor immediately. Pharmacists are also asked to contact by all means at their disposal patients who have received the drug subject to the recall in order to carry out an exchange.
A medical information service is available on 0 800 123 550.
Health
Related News :